dipperam hct 10 mg/160 mg/25 mg filmom obalené tablety
sandoz pharmaceuticals d.d., slovinsko - amlodipínium-bezylát, valsartan, hydrochlórtiazid - 58 - hypotensiva
dipperam hct 5 mg/160 mg/12,5 mg filmom obalené tablety
sandoz pharmaceuticals d.d., slovinsko - amlodipínium-bezylát, valsartan, hydrochlórtiazid - 58 - hypotensiva
rosuvastatin hetero 40 mg filmom obalené tablety
hetero europe s.l., Španielsko - rosuvastatín - 31 - hypolipidaemica
rosuvastatin hetero 20 mg filmom obalené tablety
hetero europe s.l., Španielsko - rosuvastatín - 31 - hypolipidaemica
rosuvastatin hetero 10 mg filmom obalené tablety
hetero europe s.l., Španielsko - rosuvastatín - 31 - hypolipidaemica
rosuvastatin hetero 5 mg filmom obalené tablety
hetero europe s.l., Španielsko - rosuvastatín - 31 - hypolipidaemica
benfogamma 300
wörwag pharma gmbh & co. kg, nemecko - benfotiamín - 86 - vitamina, vitagena
abiraterone mylan
mylan ireland limited - abiraterón acetátu - prostatické nádory - endocrine therapy, other hormone antagonists and related agents - abiraterone mylan is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt). the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated. the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.
ferrola
wÖrwag pharma gmbh & co.kg, nemecko - síran železnatý a kyselina listová - 12 - antianaemica
abiraterone accord
accord healthcare s.l.u. - abiraterón acetátu - prostatické nádory - endokrinná terapia - abiraterone accord is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicatedthe treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.